Critical Care Management of COVID-19 Patients

The critical care management of COVID-19 patients centres on prompt recognition of respiratory failure and the timely deployment of supportive interventions to prevent multi-organ injury. Initial assessment emphasises the severity of hypoxaemia, respiratory mechanics and the presence of comorbid conditions. Standard practice involves the escalation from supplemental oxygen through high-flow nasal cannula to invasive mechanical ventilation when indicated. Protective ventilation strategies aim to limit ventilator-induced lung injury by targeting low tidal volumes and moderate levels of positive end-expiratory pressure. Adjunctive measures such as prone positioning and neuromuscular blockade may improve oxygenation in severe cases, while extracorporeal membrane oxygenation provides a rescue modality for refractory hypoxaemia. Comprehensive care also addresses secondary complications, including acute kidney injury, coagulopathy and nosocomial infections. Multidisciplinary teams collaborate to optimise fluid balance, sedation protocols and nutritional support, while anticipating long-term rehabilitation needs. Resource allocation and capacity planning remain vital to ensure equitable access to critical therapies during surges.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Critical Care Management of COVID-19 Patients publication trend

The graph below shows the total number of articles in critical care management of covid-19 patients across all publications each year (not limited to Nature Index journals).

Technical terms

Acute respiratory distress syndrome (ARDS): A severe form of lung injury characterised by diffuse alveolar damage, inflammatory exudation and profound hypoxaemia requiring ventilatory support.

Invasive mechanical ventilation (IMV): Delivery of positive-pressure breaths via an endotracheal or tracheostomy tube to support or replace spontaneous breathing.

Extracorporeal membrane oxygenation (ECMO): An external circuit that oxygenates and removes carbon dioxide from blood, offering temporary respiratory support when conventional ventilation fails.

Hyperosmotic-hyperoncotic infusion: Intravenous administration of a high-solute-concentration solution designed to draw extravascular fluid into the circulation, thereby reducing pulmonary oedema.

References

1. Long-term survival after intensive care for COVID-19: a nationwide cohort study of more than 8000 patients. Annals of Intensive Care (2023).
2. Hypertonic treatment of acute respiratory distress syndrome. Frontiers in Bioengineering and Biotechnology (2023).
3. Rate of Intensive Care Unit admission and outcomes among patients with coronavirus: A systematic review and Meta-analysis. PLOS ONE (2020).
4. Access to intensive care in 14 European countries: a spatial analysis of intensive care need and capacity in the light of COVID-19. Intensive Care Medicine (2020).